Foley Hoag Represents Dong-A ST in $525M License Agreement with AbbVie

January 16, 2017

Foley Hoag LLP recently represented South Korean pharmaceutical company Dong-A ST in its $525 million exclusive license agreement for the global development and commercialization of its investigational immuno-oncology drug Mer tyrosine kinase inhibitor (Mer TKI) with U.S. pharmaceutical company AbbVie Inc.

Mer TKI, a small molecule in the pre-clinical phase, is known to bind to specific proteins associated with blocking the immune system from attacking cancer cells.

Under the terms of the multi-year agreement, Dong-A ST will receive $40 million upfront and be eligible to receive $485 million if certain development, regulatory and commercial milestones are met. Dong-A ST will also receive royalties of up to 10 percent on Mer TKI sales.

Upon the completion of a pre-clinical study to be jointly led by the two companies, AbbVie will be responsible for global development and regulatory filings. AbbVie will obtain global marketing rights for the product after development, while Dong-A ST will retain marketing rights in Korea.

Foley Hoag attorneys Hemmie Chang, Karen Tepichin and David Halstead advised Dong-A ST in the transaction.